[Federal Register: June 24, 2005 (Volume 70, Number 121)]
[Notices]
[Page 36644]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr24jn05-88]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Public Notice
AGENCY: Centers for Disease Control and Prevention (CDC), Health and
Human Services (HHS).
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Centers for Disease Control and Prevention (CDC), National
Center for Infectious Disease (NCID), Division of Bacterial and Mycotic
Diseases (DBMD) through its component Branches has lead technical
responsibility for a number of Category A, B and C bioterrorism agents
and their associated toxins (Bacillus anthracis, Clostridium botulinum,
Brucella sps., Burkholderia sps., Staphylococcus entertoxin B, other
food-or waterborne bacterial pathogens, and other bacterial agents).
DBMD provides technical support for the Nation's prevention and control
efforts for human anthrax disease. Since 2001, DBMD has been collecting
anthrax immune plasma from Department of Defense volunteers who
received the licensed Anthrax Vaccine Adsorbed (AVA) according to the
licensed schedule. DBMD has contracted with industry to produce anthrax
immune globulin (AIG) from the collected anthrax immune plasma using
anion-exchange chromatography. Since 2003, DBMD has been evaluating the
efficacy and pharmacokinetics of AIG in small animals. Preliminary
results of these studies are now available, and are being released to
the public domain to facilitate development of immunotherapeutic agents
for treatment of human inhalational anthrax disease. DBMD will continue
to conduct AIG studies in animals, and will release data to the public
as soon as the results become available.
Persons or organizations who are interested in receiving the
preliminary animal AIG study results, and in receiving future updates,
should contact CDC and provide a mailing address.
CDC prefers to receive requests for data electronically. These
requests can be e-mailed to the attention of Michael J. Detmer at
MDetmer@cdc.gov. Mailed responses can be sent to the following address:
Michael J. Detmer, Division of Bacterial and Mycotic Diseases, National
Center for Infectious Diseases, Centers for Disease Control and
Prevention, 1600 Clifton Rd., NE., Mail Stop C-09, Atlanta, GA 30333.
FOR FURTHER INFORMATION CONTACT: Technical: Clare A. Dykewicz, M.D.,
M.P.H. Division of Bacterial and Mycotic Diseases, National Center for
Infectious Diseases, Centers for Disease Control and Prevention (CDC),
1600 Clifton Rd. NE., Mail Stop C 09, Atlanta, GA 30333. Telephone
(404) 639-4138, e-mail: cad3@cdc.gov.
Dated: June 13, 2005.
James D. Seligman,
Associate Director for Program Services, Centers for Disease Control
and Prevention.
[FR Doc. 05-12497 Filed 6-23-05; 8:45 am]
BILLING CODE 4163-18-P